Core Insights - The company reported a revenue of 625 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.31% [1] - The net profit attributable to shareholders reached 63.99 million yuan, showing a significant year-on-year increase of 179.34% [1] - In the third quarter, the company achieved a revenue of 199 million yuan, which is a year-on-year growth of 9.77%, with a net profit of 19.32 million yuan, reflecting a year-on-year increase of 63.33% [1]

山东沃华医药科技股份有限公司 2025 年第三季度报告 证券代码：002107 证券简称：沃华医药 公告编号：2025-041 山东沃华医药科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 1 山东沃华医药科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 199,254,868.52 | 9.77% | ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-040 山东沃华医药科技股份有限公司 关于董事减持完毕的公告 近日，公司收到张戈先生出具的《关于股份减持计划实施完毕的 告知函》，截至告知函出具之日张戈先生的减持计划已实施完毕。现 将减持具体情况公告如下： 公司董事、董事会秘书张戈先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 山东沃华医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日在巨潮资讯网披露了《关于董事减持公司股份的预披露 公告》，持有公司股份 10,058,753 股（占公司总股本比例 1.74%）的 董事、董事会秘书张戈先生计划在公告之日起 15 个交易日后的 3 个 月内以集中竞价交易方式合计减持本公司股份不超过 2,514,688 股 （占本公司总股本比例 0.44%）。 一、股份减持情况 （一）股份来源：公司首次公开发行股票并上市前已发行的股份， 以及公司历年分配的红股。 1 | （二）股东减持股份情况 | | --- | | 股东 | 减持方 ...

Core Insights - The healthcare and elderly care industry is identified as a significant emerging green and low-carbon industry, serving as a crucial link for deepening cross-strait cooperation and enhancing public welfare [3] Group 1: Industry Overview - The healthcare and elderly care industry is positioned as a vital area for improving people's livelihoods and driving economic development, with substantial potential and broad prospects in Weifang [3] - Weifang is accelerating the establishment of a high-quality living environment and aims to become a new hub for medical advancements in Shandong [3] Group 2: Regional Development - Weifang High-tech Zone has a strong foundation and clear advantages, recognized as one of the top 100 biomedical industry parks in the country, with its biomedical industry park being the only one in Shandong designated as a characteristic town [3] - The High-tech Zone hosts over 30 key enterprises, including Wohu Pharmaceutical, Huachen Pharmaceutical, Haiwang Pharmaceutical, and Nuoyimaier [3] Group 3: Event Highlights - The cross-strait healthcare industry cooperation meeting served as an important platform for promoting exchanges and cooperation, providing valuable opportunities for attendees [3][4] - Experts delivered keynote speeches, and companies presented their projects, followed by targeted negotiations among interested enterprises [4]

Core Viewpoint - The company has announced its 2025 mid-year profit distribution plan, which was approved during the third extraordinary shareholders' meeting held on August 12, 2025 [1] Summary by Sections Shareholders' Meeting Approval - The profit distribution plan was approved at the third extraordinary shareholders' meeting on August 12, 2025 [1] Cash Dividend Distribution - The company will distribute a cash dividend of 1.20 yuan per 10 shares, totaling 69,265,152 yuan (including tax) [2] - No bonus shares will be issued, and no capital reserves will be converted into share capital [2] - The total dividend amount will be adjusted if there are changes in the total share capital before the record date [2] Implementation Details - The cash dividend distribution is based on a total share capital of 577,209,600 shares [2] - The distribution plan is consistent with the profit distribution plan approved by the shareholders' meeting [2] - The implementation of the plan will occur within two months of the shareholders' meeting approval [2] Key Dates - The record date for the dividend distribution is September 10, 2025, and the ex-dividend date is September 11, 2025 [3] Distribution Method - Cash dividends will be directly credited to the accounts of A-share shareholders through their securities companies on the ex-dividend date [4] - The company will handle the distribution for specific shareholders as listed [4] Consultation Information - Contact details for inquiries are provided, including the address and phone number [4]

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 1.20 yuan (including tax) for every 10 shares held by shareholders [2] - The record date for the dividend distribution is set for September 10, 2025, and the ex-dividend date will be September 11, 2025 [2]

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 1.20 yuan (including tax) for every 10 shares held [1] - The total number of shares used as the basis for the distribution is 577,209,600 [1] - The record date for the dividend distribution is set for September 10, 2025, with the ex-dividend date on September 11, 2025 [1]

证券代码：002107 证券简称：沃华医药 公告编号：2025-039 山东沃华医药科技股份有限公司 2025 年中期权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称公司）2025 年中期 权益分派方案已获 2025 年 8 月 12 日召开的公司 2025 年第三次临时 股东会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过权益分派方案情况 （一）2025 年 8 月 12 日，公司 2025 年第三次临时股东会审议 通过了《关于 2025 年中期利润分配预案》（以下简称利润分配方案）。 根据该方案，公司以现有总股本 577,209,600 股为基数，向全体股东 每10股派发现金红利1.20元（含税），共计派发现金红利69,265,152.00 元（含税），不送红股，不以公积金转增股本。上述利润分配方案披 露后至权益分派实施公告确定的股权登记日前，公司总股本发生变动 的，公司将按照每股分红金额不变的原则，相应调整分红总额。 （二）自利润分配方案披露至实施期间，公司股本总额未发生变 化。 （三）本 ...

Core Viewpoint - Wowo Pharmaceutical (002107.SZ) announced a cash dividend distribution plan for the mid-term of 2025, indicating a commitment to returning value to shareholders [1] Group 1 - The company will distribute a cash dividend of 1.20 yuan (including tax) for every 10 shares held, based on a total of 577,209,600 shares [1] - The record date for the dividend distribution is set for September 10, 2025, and the ex-dividend date is September 11, 2025 [1]

Market Overview - The Shanghai Composite Index closed at 3800.35 points, with a decline of 1.76% [1] - The total trading volume of A-shares reached 31,977.88 billion yuan [1] Technical Analysis - A total of 150 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Hengyu Xintong: 5-day MA at 76.38 yuan, 10-day MA at 77.37 yuan, difference of -1.28% [1] - ST Huayang: 5-day MA at 11.72 yuan, 10-day MA at 11.84 yuan, difference of -0.94% [1] - Wohua Pharmaceutical: 5-day MA at 6.96 yuan, 10-day MA at 7.02 yuan, difference of -0.78% [1] Individual Stock Performance - Hengyu Xintong: Today's decline of 5.98%, with a turnover rate of 14.00% [1] - ST Huayang: Today's decline of 5.04%, with a turnover rate of 0.09% [1] - Wohua Pharmaceutical: Today's decline of 3.03%, with a turnover rate of 3.42% [1] - Other notable declines include: - Longshen: -3.62% [1] - Zhuhua Design: -5.51% [1] - Dadi Ocean: -7.20% [1] Additional Stock Data - The following stocks also showed significant declines: - Kexin Technology: -2.56% [1] - Chenxi: -5.85% [1] - Yuxing Co.: -7.53% [1] - Yingjian Technology: -6.08% [1] - Senhe Co.: -6.08% [1] - Huayuan Holdings: -3.42% [1]